Ostro is off to a fast start in 2025, driven by growing demand for its AI-powered tools and fresh wins in rare disease. In January, the company partnered with the Desmoid Tumor Research Foundation to bring its technology to the DTRF website, helping patients and caregivers quickly find relevant information using intuitive search and navigation. Built in collaboration with DTRF’s Patient Advocacy Committee, the effort underscores Ostro’s focus on delivering better digital experiences where patients often face the most friction.
The company’s platform–anchored by tools like Tailor, a compliant AI search layer launched last year, and Navigate, which integrates live nurse navigators–is driving measurable outcomes for life sciences brands. One rare disease partner saw a 150% jump in call-to-action starts and a 40% lift in completions, while Navigate turned 97% of negative user interactions into positive ones. Backed by engineering talent from Google, Amazon, and Hims & Hers, and built with compliance at its core, Ostro’s technology powered over 1.3 million interactions last year–proof that the tools are resonating with real users.
As 2025 picks up, Ostro is doubling down on AI-driven personalization, aiming to serve up the right resource–whether a copay card, educational guide, or safety study–at the exact moment it’s needed. With more life sciences brands looking to move beyond static websites and generic messaging, Ostro is making the case that compliant, consumer-grade design isn’t just possible–it’s becoming essential.
